PLA2G7 and early-onset autosomal dominant Alzheimer disease: A randomized and double-blind clinical trial under phase 2a provided preliminary evidence that the inhibition of Lp-PLA2 by administration of 250 mg rilapladib may attenuate the progression of Alzheimer's disease [62].